Akero Therapeutics Statistics
Total Valuation
AKRO has a market cap or net worth of $3.18 billion. The enterprise value is $2.64 billion.
Important Dates
The next estimated earnings date is Friday, May 9, 2025, before market open.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AKRO has 79.62 million shares outstanding. The number of shares has increased by 27.71% in one year.
| Current Share Class | 79.62M |
| Shares Outstanding | 79.62M |
| Shares Change (YoY) | +27.71% |
| Shares Change (QoQ) | +1.63% |
| Owned by Insiders (%) | 1.41% |
| Owned by Institutions (%) | 79.16% |
| Float | 66.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.12 |
| P/TBV Ratio | 4.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.38, with a Debt / Equity ratio of 0.05.
| Current Ratio | 19.38 |
| Quick Ratio | 18.69 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -61.14 |
Financial Efficiency
Return on equity (ROE) is -39.22% and return on invested capital (ROIC) is -26.47%.
| Return on Equity (ROE) | -39.22% |
| Return on Assets (ROA) | -25.37% |
| Return on Invested Capital (ROIC) | -26.47% |
| Return on Capital Employed (ROCE) | -36.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.00M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +74.72% in the last 52 weeks. The beta is -0.20, so AKRO's price volatility has been lower than the market average.
| Beta (5Y) | -0.20 |
| 52-Week Price Change | +74.72% |
| 50-Day Moving Average | 45.49 |
| 200-Day Moving Average | 32.07 |
| Relative Strength Index (RSI) | 42.72 |
| Average Volume (20 Days) | 954,522 |
Short Selling Information
The latest short interest is 5.20 million, so 6.54% of the outstanding shares have been sold short.
| Short Interest | 5.20M |
| Short Previous Month | 5.05M |
| Short % of Shares Out | 6.54% |
| Short % of Float | 7.84% |
| Short Ratio (days to cover) | 5.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -285.42M |
| Pretax Income | -204.18M |
| Net Income | -252.06M |
| EBITDA | -285.41M |
| EBIT | -285.42M |
| Earnings Per Share (EPS) | -$3.75 |
Full Income StatementBalance Sheet
The company has $743.08 million in cash and $36.12 million in debt, giving a net cash position of $761.71 million or $9.57 per share.
| Cash & Cash Equivalents | 743.08M |
| Total Debt | 36.12M |
| Net Cash | 761.71M |
| Net Cash Per Share | $9.57 |
| Equity (Book Value) | 750.11M |
| Book Value Per Share | 10.36 |
| Working Capital | 730.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$230.11 million and capital expenditures -$999,000, giving a free cash flow of -$231.11 million.
| Operating Cash Flow | -230.11M |
| Capital Expenditures | -999,000 |
| Free Cash Flow | -231.11M |
| FCF Per Share | -$2.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |